Stock Taper
SCREENER COMPARE ANY 2 STOCKS
CELC
CELCUITY INC.
NASDAQ
$95.70
▼ DOWN 0.76% (-0.73)

KEY STATISTICS

Market Cap$4.67 B
52w High$151.02
52w Low$44.42
Dividend Yield—
Frequency—
P/E-22.26
Volume515.51K
Shares Out.48.77M

COMPANY

LEADERSHIP

Brian F. Sullivan
CHIEF EXECUTIVE
Brian F. Sullivan

COMPENSATION 2026

Salary$577,096
Stock Awards$0
Incentive Plan Pay$368,122
All Other Comp.$0
Total$16,373,868

ABOUT

SECTOR
Healthcare
WENT PUBLIC
September 19, 2017
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
155

PRICE TARGET

Target High$178.00
Target Low$110.00
Target Median$155.00
Target Consensus$154.33

UPCOMING EARNINGS

DateNov 11, 2026
DayWednesday
Rev. Est.$4.26M
NOV
11
WED

PRICE

$95.70 ▼ DOWN 0.76% (−$0.73)
$94.50$95.25$96.00$96.759:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM95.70

About Celcuity Inc.

https://www.celcuity.com ↗

Celcuity Inc. develops targeted cancer therapies and diagnostics, including Gedatolisib and CELsignia tests, focusing on personalized treatment for breast and ovarian cancers in the U.S.

INDUSTRY

Biotechnology

A PRODUCT CELCUITY INC. IS KNOWN FOR

Gedatolisib
Gedatolisib

Gedatolisib is a first-in-class PI3K/AKT/mTOR inhibitor in Phase 3 for breast cancer, with an NDA submitted to the FDA, highlighting its potential as a key cancer therapy.

COMPETITORS

COMPETITOR
BBIO COMPARE
CRIS COMPARE
RLAY COMPARE
SN SNSE COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
116
LISTED HERE
26
RANKED BY POSITION SIZE
VTS.AX
0.01% · 1.4M
XBI
1.00% · 1.2M
XSU.TO
0.11% · 979.2K
SCHA
0.08% · 180.6K
FESM
0.09% · 63.0K
CANC
1.91% · 43.1K
LABU
0.66% · 40.0K
XRS2.DE
0.12% · 33.9K
USVM
0.12% · 22.9K
RSSL
0.12% · 18.4K
GSSC
0.09% · 10.0K
BBSC
0.08% · 6.4K
SGRW
1.24% · 3.6K
BBC
0.67% · 3.5K
ACSG
0.40% · 2.1K
PRFZ
0.01% · 1.9K
RTWO.L
0.08% · 1.8K
HELX
0.49% · 1.6K
STXK
0.18% · 1.6K
ESSC
0.37% · 1.5K
RFLR
0.15% · 1.5K
URTY
0.05% · 1.5K
BKSE
0.12% · 1.1K
VETS
0.28% · 596
USUE.DE
0.01% · 124
RESM
0.12% · 76

INSTITUTIONAL OWNERSHIP

SHARES OWNED
72.00%
HOLDERS
374
TOP 12 OF 374 · RANKED BY POSITION SIZE
Baker Bros. Advisors LP
7.9M sh · $789.52M
Nea Management Company, LLC
3.5M sh · $352.64M
Avoro Capital Advisors LLC
3.4M sh · $355.71M
Rtw Investments, LP
3.3M sh · $345.76M
Perceptive Advisors LLC
3.2M sh · $334.49M
Blackrock, Inc.
3.0M sh · $315.83M
Vanguard Group Inc
2.3M sh · $227.35M
State Street Corp
2.0M sh · $204.56M
Soleus Capital Management, L.P.
1.8M sh · $180.36M
Deerfield Management Company, L.P. (Series C)
1.7M sh · $195.64M
Morgan Stanley
1.5M sh · $74.73M
Bank Of America Corp /De/
1.5M sh · $153.93M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity5
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

TRADES BY CONGRESS

HOUSE TRADES
Tom Malinowski
Tom Malinowski
Sale (Full)
2021-05-26

INSIDER TRADES

★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Sullivan Brian F.
Purchase · 80.0K shares
2026-08-14
★
DIRECTOR, OFFICER: CHIEF SCIENCE OFFICER
Laing Lance G.
Purchase · 20.0K shares
2026-08-14
★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Sullivan Brian F.
Purchase · 120.0K shares
2026-08-14
★
OFFICER: CHIEF FINANCIAL OFFICER
Hahne Vicky
Purchase · 10.0K shares
2026-08-14

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 6
MARKET OUTPERFORM 1
OVERWEIGHT 1
8 GRADES IN THE LAST 12 MONTHS
Guggenheim BUY Citizens MARKET OUTPERFORM Stifel BUY Needham BUY HC Wainwright & Co. BUY Wells Fargo OVERWEIGHT Craig-Hallum BUY Jefferies BUY

SECTORS PEERS

PEERPRICE
APGE$135.07COMPARE
CGON$74.46COMPARE
TVTX$65.57COMPARE
XENE$59.77COMPARE
LEGN$21.61COMPARE
IRON$79.95COMPARE
ZLAB$26.39COMPARE
RARE$15.69COMPARE